AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01313559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT01313559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT03620760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: Ticagrelor (AZD6140) 45 mg twice daily dose
Study NCT03620760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily dose
Study NCT03620760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily dose
Study NCT01491373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/LT-CAGE® Device
Description: rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
Study NCT01491373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/LT-CAGE® Device
Description: LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
Study NCT00673439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
Study NCT00673439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
Study NCT03449732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth
Study NCT03911232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: standard general anesthesia protocol with sugammadex
Study NCT01723800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO
Study NCT01723800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01723800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01723800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02802137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafluprost
Study NCT01723800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01723800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT05328739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care
Description: home care program
Study NCT02010957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG positron emission tomography
Description: 2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
Study NCT02010957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodometomidate imaging
Description: 2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
Study NCT01391858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lyrica
Description: 150mg of pregabalin/placebo
Study NCT01391858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyrica
Description: 150mg of pregabalin/placebo
Study NCT01313559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT02802137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafluprost and dorzolamide/timolol
Study NCT00358735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare CECT device
Description: Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
Study NCT00358735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
Study NCT02297152 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FLIP HOLE
Description: The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
Study NCT01817972 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: Subcutaneous injection
Study NCT01817972 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab pegol
Description: Subcutaneous injection
Study NCT01817972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 50mg tablets
Study NCT01032941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
Study NCT01032941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
Study NCT04157829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scintilling lamp
Description: Lamp with a standardized scintilling
Study NCT04157829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classic lamp
Description: Lamp without a scintilling
Study NCT03313154 — intervention group
Intervention type: OTHER
Intervention: Neuropsychiatric screening
Description: Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R).
Study NCT01150409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
Study NCT01150409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
Study NCT01150409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
Study NCT02102529 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic colonic surgery
Description: women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
Study NCT06568991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Protein Rice MATSUBUMAI
Description: Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group.
Study NCT06568991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein Rice MATSUBUMAI
Description: Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group.
Study NCT03622086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundations of Fitness Program
Description: The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
Study NCT04425369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-sided approaches for iliac crest bone graft
Description: Only one side of the ilium was exposed when surgery.
Study NCT01803035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 1 %
Study NCT01803035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 2 %
Study NCT01803035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study NCT00227734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and oxaliplatin + cetuximab
Description: cetuximab
Study NCT00227734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and oxaliplatin
Description: capecitabine and oxaliplatin without cetuximab
Study NCT01550068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Study NCT04138602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella
Description: Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Study NCT04138602 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham BTL Emsella
Description: Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
Study NCT05397288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Description: A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period
Study NCT05397288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (A)
Description: A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period
Study NCT05397288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education (E)
Description: A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~* 1st month: group talk (1 time/week), individual consultation (2 times/week)~* 2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~* 3rd month: group talk (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period
Study NCT03113175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
Study NCT03113175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations-Liaison
Description: Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
Study NCT00886015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TT Clamp
Description: trichiasis surgery performed with TT clamp
Study NCT00886015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard BLTR Technique
Description: bilamellar tarsal rotation procedure in trichiasis surgery
Study NCT01395147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
Study NCT06266325 — intervention group
Intervention type: OTHER
Intervention: There is no intervention. Exposures are predictor variables of mortality.
Description: Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
Study NCT01161069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral solution, given once daily for 14 days
Study NCT03312244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine 180mg/day p.o.
Study NCT03312244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04675099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pCARE
Description: Mothering from the Inside Out is an evidence-based intervention delivered in substance use treatment settings that helps mothers with substance use disorders foster parent-child attachment, cope with stressful parenting situations, and promote their child's healthy development. This 3 month counseling intervention both improves parent-child attachment and decreases rates of drug relapse among mothers. The proposed mechanism of action targeted by the intervention is a change in parental reflective functioning, defined as the capacity to recognize and make sense of mental states (especially emotional states) and understand how they influence behavior and relationships.
Study NCT04675099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Early Intervention services
Description: The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
Study NCT04675099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Early Intervention services
Description: The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
Study NCT00218595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Dialectical behavior therapy plus opiate replacement medication.
Study NCT00218595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I/GDC
Description: Individual and group drug counseling plus opiate replacement medication.
Study NCT00811733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
Study NCT06438614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HITS
Description: Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF. Irinotecan 50mg/m2/day IV will be administered from day 1-5concurrently with temozolomide 150mg/m2/day orally. Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11
Study NCT06438614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab + GM-CSF cycles
Description: Patients that achieve CR after 2 or 4 cycles of HITS will move on to 5 cycles of Naxitamab + GM-CSF cycles.
Study NCT06438614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NICE
Description: Patients that do not have an objective response (CR/PR) will receive NICE within 3 weeks from last dose. Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2). Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and 11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11. Ifosfamide 1.5 gr/m2/day IV will be administered from day 1-3 concurrently with etoposide 100 mg/m2/day IV. Carboplatin 400 mg/m2/day IV will be administered on day 1
Study NCT00459862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT00459862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally
Study NCT02902588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG-PULSION
Description: Intravenous administration of indocyanine green
Study NCT02902588 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LiMON, Pulsion Medical Systems
Description: Application of near infrared light
Study NCT02902588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium (Gadovist, Bayer, Germany)
Description: Injection of gadolinium